摘要
肿瘤患者代谢异常，即肿瘤代谢重编程， 是肿瘤发生发展的重要标志之一。肿瘤细胞快速生长的特性促使其争夺更多营养补给，高能量的需求和低获能的有氧糖酵解方式让机体功能蛋白被当作能源使用，导致体内蛋白质含量无法满足患者正常生理需要。全身的骨骼肌是人体最大的蛋白质储存库，肿瘤细胞复杂的营养代谢及蛋白质过度消耗会导致患者肌肉质量减少、肌肉功能下降。笔者团队最初研究发现，腹部肿瘤患者在经历了围术期的禁食及胃肠道手术改建等因素的影响后普遍会发生术后疲劳综合征，骨骼肌功能显著下降。通过进一步临床研究，无论是否存在营养风险，肌肉减少症都是胃肠肿瘤患者预后的独立预测因素。因此，肌肉减少症是肿瘤患者围术期的关注要点，将之纳入肿瘤患者的术前常规筛查亦具有重要临床意义。对合并肌肉减少症的肿瘤患者进行适当干预有助于促进术后加速康复，改善手术预后，对提高肿瘤患者术后生活质量和减轻公共医疗卫生负担具有重要意义。
Abstract
Abnormal metabolism in tumor patients， known as the metabolic reprogramming of tumor is one of the key characteristics of tumorigenesis. The rapid-growth tumor is compelled to compete for more nutrient. The need for high energy and low-energy aerobic glycolysis allow the body’s functional proteins to be used as energy， making it difficult to meet the normal physiological needs of patients. The complex nutritional metabolism of tumors and excessive protein consumption can reduce muscle mass and impair muscle function in cancer patients. The initial research of our team found that postoperative fatigue syndrome generally occurs in patients with abdominal tumors， and skeletal muscle function was significantly decreased after undergoing perioperative fasting and gastrointestinal surgery remodeling. Further clinical studies indicated that sarcopenia is an independent predictor of prognosis in patients with gastrointestinal tumors regardless of nutritional risk. Therefore， sarcopenia is an important concern for tumor patients during the perioperative period. It is of great clinical significance to include the diagnostic standard of sarcopenia in routine screening for tumor patients before surgery. It would enhance recovery after surgery and improve clinical outcomes if proper clinical interventions were carried out for the tumor patients with sarcopenia， and it would improve the life quality of tumor patients and reduce healthcare costs.
关键词
肌肉减少症 /
肿瘤 /
代谢 /
预后
Key words
Sarcopenia /
Tumor /
Metabolic /
Prognosis
邹红波，严夏霖，余鼎业，余震.
肿瘤患者肌肉减少症的诊治进展[J]. 肿瘤代谢与营养电子杂志. 2020, 7(2): 250-254 https://doi.org/10.16689/j.cnki.cn11-9349/r.2020.02.022
Zou Hongbo， Yan Xialin，Yu Dingye， Yu Zhen.
Research progress on diagnosis and treatment of sarcopenia in tumor patients[J]. Electronic Journal of Metabolism and Nutrition of Cancer. 2020, 7(2): 250-254 https://doi.org/10.16689/j.cnki.cn11-9349/r.2020.02.022
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
1.DE BARI L， ATLANTE A. Including the mitochondrial metabolism of L-lactate in cancer metabolic reprogramming［J］. Cell Mol Life Sci， 2018， 75（15）: 2763-2776.
2.MARTINEZ-OUTSCHOORN U E， PEIRIS-PAGES M， PESTELL R G， et al. Cancer metabolism: a therapeutic perspective［J］. Nat Rev Clin Oncol， 2017， 14（1）: 11-31.
3.HEINDEL J J， BLUMBERG B， CAVE M， et al. Metabolism disrupting chemicals and metabolic disorders［J］. Reprod Toxicol， 2017， 68: 3-33.
4.LU W， CAO F， WANG S， et al. LncRNAs: The regulator of glucose and lipid metabolism in tumor cells［J］. Front Oncol， 2019， 9: 1099.
5.LI Z， ZHANG H. Reprogramming of glucose， fatty acid and amino acid metabolism for cancer progression［J］. Cell Mol Life Sci， 2016， 73（2）: 377-392.
6.BOENGLER K， KOSIOL M， MAYR M， et al. Mitochondria and ageing: role in heart， skeletal muscle and adipose tissue［J］. J Cachexia Sarcopenia Muscle， 2017， 8（3）: 349-369.
7.CRUZ-JENTOFT A J， BAHAT G， BAUER J， et al. Sarcopenia: revised European consensus on definition and diagnosis［J］. Age Ageing， 2019， 48（1）: 16-31.
8.CHEN X Y， LI B， MA B W， et al. Sarcopenia is an effective prognostic indicator of postoperative outcomes in laparoscopic-assisted gastrectomy［J］. Eur journal surg oncol， 2019， 45（6）: 1092-1108.
9.ZHUANG C L， HUANG D D， PANG W Y， et al. Sarcopenia is an independent predictor of severe postoperative complications and long-term survival after radical gastrectomy for gastric cancer: analysis from a large-scale cohort［J］. Medicine （Baltimore）， 2016， 95（13）: e3164.
10.HUANG D D， ZHOU C J， WANG S L， et al. Impact of different sarcopenia stages on the postoperative outcomes after radical gastrectomy for gastric cancer［J］. Surgery， 2017， 161（3）: 680-693.
11.HUANG D D， WANG S L， ZHUANG C L， et al. Sarcopenia， as defined by low muscle mass， strength and physical performance， predicts complications after surgery for colorectal cancer［J］. Colorectal Dis， 2015， 17（11）: 256-264.
12.MA B W， CHEN X Y， FAN S D， et al. Impact of sarcopenia on clinical outcomes after radical gastrectomy for patients without nutritional risk［J］. Nutrition， 2019， 61: 61-66.
13.von Haehling S， Morley J E， Anker S D. An overview of sarcopenia: facts and numbers on prevalence and clinical impact［J］. J Cachexia Sarcopenia Muscle， 2010， 1（2）: 129-133.
14.ZHOU C J， ZHANG F M， ZHANG F Y， et al. Sarcopenia: a new predictor of postoperative complications for elderly gastric cancer patients who underwent radical gastrectomy［J］. J Surg Res， 2017， 211: 137-146.
15.HUANG D D， CHEN X X， CHEN X Y， et al. Sarcopenia predicts 1-year mortality in elderly patients undergoing curative gastrectomy for gastric cancer: a prospective study［J］. J Cancer Res Clin Oncol， 2016， 142（11）: 2347-2356.
16.KOBAYASHI A， KAIDO T， HAMAGUCHI Y， et al. Impact of sarcopenic obesity on outcomes in patients undergoing hepatectomy for hepatocellular carcinoma［J］. Ann Surg， 2019， 269（5）: 924-931.
17.FELICIANO E M C， KROENKE C H， MEYERHARDT J A， et al. Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: results from the C SCANS study［J］. JAMA Oncol， 2017， 3（12）: e172319.
18.CAAN B J， CESPEDES FELICIANO E M， PRADO C M， et al. Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer［J］. JAMA oncology， 2018， 4（6）: 798-804.
19.CHEN L K， WOO J， ASSANTACHAI P， et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment［J］. J Am Med Dir Assoc， 2020， 21（3）: 300-307.
20.CRUZ-JENTOFT A J， SAYER A A. Sarcopenia［J］. Lancet， 2019， 393（10191）: 2636-2646.
21.MOURTZAKIS M， PRADO C M M， LIEFFERS J R， et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care［J］. Appl Physiol Nutr Metab， 2008， 33（5）: 997-1006.
22.ZHUANG C L， SHEN X， HUANG Y Y， et al. Myosteatosis predicts prognosis after radical gastrectomy for gastric cancer: a propensity score-matched analysis from a large-scale cohort［J］. Surgery， 2019， 166（3）: 297-304.
23.ONDER G， PENNINX B W J H， BALKRISHNAN R， et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study［J］. Lancet， 2002， 359（9310）: 926-930.
24.DENT E， MORLEY J E， CRUZ-JENTOFT A J， et al. International Clinical Practice Guidelines for Sarcopenia （ICFSR）: screening， diagnosis and management［J］. J Nutr Health Aging， 2018， 22（10）: 1148-1161.
25.YAMAMOTO K， NAGATSUMA Y， FUKUDA Y， et al. Effectiveness of a preoperative exercise and nutritional support program for elderly sarcopenic patients with gastric cancer［J］. Gastric Cancer， 2017， 20（5）: 913-918.
26.CEREDA E， TURRI A， KLERSY C， et al. Whey protein isolate supplementation improves body composition， muscle strength， and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy［J］. Cancer Med， 2019， 8（16）: 6923-6932.
27.BAUER J M， VERLAAN S， BAUTMANS I， et al. Effects of a vitamin D and leucine-enriched whey protein nutritional supplement on measures of sarcopenia in older adults， the PROVIDE study: a randomized， double-blind， placebo-controlled trial［J］. J Am Med Dir Assoc， 2015， 16（9）: 740-747.
28.HOLEC∨EK M. Beta-hydroxy-beta-methylbutyrate supplementation and skeletal muscle in healthy and muscle-wasting conditions［J］. J Cachexia Sarcopenia Muscle， 2017， 8（4）: 529-541.
29.SHEA M K， FIELDING R A， DAWSON-HUGHES B. The effect of vitamin D supplementation on lower-extremity power and function in older adults: a randomized controlled trial［J］. Am J Clin Nutr， 2019， 109（2）: 369-379.
30.CHEUNG W W， HAO S， WANG Z， et al. Vitamin D repletion ameliorates adipose tissue browning and muscle wasting in infantile nephropathic cystinosis-associated cachexia［J］. J Cachexia Sarcopenia Muscle， 2019， 11（1）: 120-134
31.CRUZ-JENTOFT A J， DAWSON HUGHES B， SCOTT D， et al. Nutritional strategies for maintaining muscle mass and strength from middle age to later life: a narrative review［J］. Maturitas， 2020， 132: 57-64.
32.BURT L A， BILLINGTON E O， ROSE M S， et al. Effect of high-dose vitamin D supplementation on volumetric bone density and bone strength: a randomized clinical trial［J］. JAMA， 2019， 322（8）: 736-745.
33.CANDOW D G， FORBES S C， CHILIBECK P D， et al. Effectiveness of creatine supplementation on aging muscle and bone: focus on falls prevention and inflammation［J］. J Clin Med， 2019， 8（4）. pii: E488.
34.WYSS M， KADDURAH-DAOUK R. Creatine and creatinine metabolism［J］. Physiol Rev， 2000， 80（3）: 1107-1213.
35.TAN S， ZHOU F， LI N， et al. Anti-fatigue effect of ginsenoside Rb1 on postoperative fatigue syndrome induced by major small intestinal resection in rat［J］. Biol Pharm Bull， 2013， 36（10）: 1634-1639.
36.TAN S J， LI N， ZHOU F， et al. Ginsenoside Rb1 improves energy metabolism in the skeletal muscle of an animal model of postoperative fatigue syndrome［J］. J Surg Res， 2014， 191（2）: 344-349.
37.ZHUANG C L， MAO X Y， LIU S， et al. Ginsenoside Rb1 improves postoperative fatigue syndrome by reducing skeletal muscle oxidative stress through activation of the PI3K/Akt/Nrf2 pathway in aged rats［J］. Eur J Pharmacol， 2014， 740: 480-487.
38.CHEN W Z， LIU S， CHEN F F， et al. Prevention of postoperative fatigue syndrome in rat model by ginsenoside Rb1 via down-regulation of inflammation along the NMDA receptor pathway in the hippocampus［J］. Biol Pharm Bull， 2015， 38（2）: 239-247.
39.HUANG D D， FAN S D， CHEN X Y， et al. Nrf2 deficiency exacerbates frailty and sarcopenia by impairing skeletal muscle mitochondrial biogenesis and dynamics in an age-dependent manner［J］. Exp Gerontol， 2019， 119: 61-73.
40.CONTE E， CAMERINO G M， MELE A， et al. Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia［J］. J Cachexia Sarcopenia Muscle， 2017， 8: （3）: 386-404.
41.LA COLLA A， PRONSATO L， MILANESI L， et al. 17β-Estradiol and testosterone in sarcopenia: Role of satellite cells［J］. Ageing Res Rev， 2015， 24（Pt B）: 166-177.
42.WRIGHT T J， DILLON E L， DURHAM W J， et al. A randomized trial of adjunct testosterone for cancer-related muscle loss in men and women［J］. J Cachexia Sarcopenia Muscle， 2018， 9（3）: 482-496.
基金
国家自然科学基金（81770884，81800795）
PDF(442 KB)
